MENU

EPRX Stock Tickeron detected bullish Stock Pattern: Pennant EPRX on May 27, 2025, netting in a 21.26% gain over 1 month

A.I.dvisor
at Tickeron.com
Loading...
+21.26% Gain from a Successful pattern Pennant
EPRX - Eupraxia Pharmaceuticals
Tickeron
Ticker: EPRX
Company: Eupraxia Pharmaceuticals
Gain: +21.26%
Confirmed: 05/27/25
Succeeded: 06/26/25
Total length: 36 days
On May 21, 2025, A.I.dvisor detected a Pennant Pattern (Bullish) for Eupraxia Pharmaceuticals (EPRX, $3.81). On May 27, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $5.01. 30 days later, on June 26, 2025, EPRX reached the target price resulting in a +2 for traders who took a long position in the stock.

EPRX in +3.30% Uptrend, rising for three consecutive days on June 23, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EPRX advanced for three days, in of 54 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 16, 2025. You may want to consider a long position or call options on EPRX as a result. In of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EPRX just turned positive on June 16, 2025. Looking at past instances where EPRX's MACD turned positive, the stock continued to rise in of 28 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 71 cases where EPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EPRX broke above its upper Bollinger Band on June 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (80.000) is normal, around the industry mean (16.566). P/E Ratio (0.000) is within average values for comparable stocks, (58.942). EPRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.298). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.026).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
EPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
201-2067 Cadboro Bay Road
Phone
+1 250 590-3968
Employees
21
Web
https://www.eupraxiapharma.com